RO 318220

Drug Profile

RO 318220

Latest Information Update: 27 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Nonindustrial source; Roche
  • Class Antiasthmatics; Antihyperlipidaemics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Atherosclerosis; Brain cancer; Coronary artery restenosis; Transplant rejection

Most Recent Events

  • 21 Jan 1999 A preclinical study has been added to the Cancer pharmacodynamics section
  • 21 Dec 1998 Preclinical development for Brain cancer in USA (Unknown route)
  • 06 Aug 1998 No-Development-Reported for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top